This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the launch and potential benefits of Teva's generic version of Axiron ® , which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to:
Those who believe in the use of DHEA claim that it relieves the menopausal symptoms described above without increasing the risk of breast cancer or cancer of the endometrium (lining to the uterus). The risk of each of these cancers may be increased with regular, prescription hormone replacement therapy. There is no proof, however, that DHEA does not stimulate these cancers as well. Women with breast cancer tend to have low levels of this hormone in their bodies. But replacement may lead to either inhibition or stimulation of growth of breast cancer cells.